Sci Rep:全外显子罕见变异分析鉴定了3个新的前列腺癌诱发性基因

2019-12-10 AlexYang MedSci原创

由于前列腺癌是高度可遗传的,与前列腺癌相关的常见变异已经在各种群体中有所研究,包括了韩国群体。然而,稀有的和低频变异对疾病的遗传也具有明显的影响。到目前为止,韩国群体中稀有变异对前列腺癌易感性的贡献情况还没有系统的评估。最近,有研究人员对7258名个体(985个前列腺癌案例和6273名对照)进行了大规模的全外显子组稀有变异分析。研究总共发现了19个稀有变异位点,覆盖了7个基因,且与前列腺癌的易感性

由于前列腺癌是高度可遗传的,与前列腺癌相关的常见变异已经在各种群体中有所研究,包括了韩国群体。然而,稀有的和低频变异对疾病的遗传也具有明显的影响。到目前为止,韩国群体中稀有变异对前列腺癌易感性的贡献情况还没有系统的评估。

最近,有研究人员对7258名个体(985个前列腺癌案例和6273名对照)进行了大规模的全外显子组稀有变异分析。研究总共发现了19个稀有变异位点,覆盖了7个基因,且与前列腺癌的易感性相关。除了已知的易感基因外,研究人员见顶了3个新的基因,包括了非编码RNAs ENTPD3-AS1、LOC102724438和蛋白编码基因SPATA3。另外,研究人员基于变异和基因鉴定了6个相关的途径,包括了雌激素信号途径、MST1信号、IL-15信号、MSP-RON信号途径和IL-12信号和巨噬细胞的产生,这些均与前列腺癌相关。

最后,研究人员指出,他们报道了韩国人群中与前列腺癌易感性相关的新的基因和稀有变异。他们的研究阐述了实现精准医疗基础目标的一种途径,即鉴定具有更高疾病风险亚群的生物标记。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1636061, encodeId=16911636061e2, content=<a href='/topic/show?id=7af1e9545b1' target=_blank style='color:#2F92EE;'>#罕见变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79545, encryptionId=7af1e9545b1, topicName=罕见变异)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17f122575821, createdName=夏天与十三菇凉, createdTime=Fri Feb 21 05:46:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342624, encodeId=0bab1342624ff, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Thu Dec 12 04:46:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467504, encodeId=712c146e504c3, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Thu Dec 12 04:46:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619063, encodeId=f6c2161906305, content=<a href='/topic/show?id=492a42862bd' target=_blank style='color:#2F92EE;'>#外显子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42862, encryptionId=492a42862bd, topicName=外显子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Dec 12 04:46:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040616, encodeId=b28e10406167b, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Dec 10 16:46:00 CST 2019, time=2019-12-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1636061, encodeId=16911636061e2, content=<a href='/topic/show?id=7af1e9545b1' target=_blank style='color:#2F92EE;'>#罕见变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79545, encryptionId=7af1e9545b1, topicName=罕见变异)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17f122575821, createdName=夏天与十三菇凉, createdTime=Fri Feb 21 05:46:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342624, encodeId=0bab1342624ff, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Thu Dec 12 04:46:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467504, encodeId=712c146e504c3, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Thu Dec 12 04:46:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619063, encodeId=f6c2161906305, content=<a href='/topic/show?id=492a42862bd' target=_blank style='color:#2F92EE;'>#外显子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42862, encryptionId=492a42862bd, topicName=外显子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Dec 12 04:46:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040616, encodeId=b28e10406167b, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Dec 10 16:46:00 CST 2019, time=2019-12-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1636061, encodeId=16911636061e2, content=<a href='/topic/show?id=7af1e9545b1' target=_blank style='color:#2F92EE;'>#罕见变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79545, encryptionId=7af1e9545b1, topicName=罕见变异)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17f122575821, createdName=夏天与十三菇凉, createdTime=Fri Feb 21 05:46:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342624, encodeId=0bab1342624ff, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Thu Dec 12 04:46:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467504, encodeId=712c146e504c3, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Thu Dec 12 04:46:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619063, encodeId=f6c2161906305, content=<a href='/topic/show?id=492a42862bd' target=_blank style='color:#2F92EE;'>#外显子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42862, encryptionId=492a42862bd, topicName=外显子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Dec 12 04:46:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040616, encodeId=b28e10406167b, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Dec 10 16:46:00 CST 2019, time=2019-12-10, status=1, ipAttribution=)]
    2019-12-12 syscxl
  4. [GetPortalCommentsPageByObjectIdResponse(id=1636061, encodeId=16911636061e2, content=<a href='/topic/show?id=7af1e9545b1' target=_blank style='color:#2F92EE;'>#罕见变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79545, encryptionId=7af1e9545b1, topicName=罕见变异)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17f122575821, createdName=夏天与十三菇凉, createdTime=Fri Feb 21 05:46:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342624, encodeId=0bab1342624ff, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Thu Dec 12 04:46:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467504, encodeId=712c146e504c3, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Thu Dec 12 04:46:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619063, encodeId=f6c2161906305, content=<a href='/topic/show?id=492a42862bd' target=_blank style='color:#2F92EE;'>#外显子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42862, encryptionId=492a42862bd, topicName=外显子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Dec 12 04:46:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040616, encodeId=b28e10406167b, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Dec 10 16:46:00 CST 2019, time=2019-12-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1636061, encodeId=16911636061e2, content=<a href='/topic/show?id=7af1e9545b1' target=_blank style='color:#2F92EE;'>#罕见变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79545, encryptionId=7af1e9545b1, topicName=罕见变异)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17f122575821, createdName=夏天与十三菇凉, createdTime=Fri Feb 21 05:46:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342624, encodeId=0bab1342624ff, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Thu Dec 12 04:46:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467504, encodeId=712c146e504c3, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Thu Dec 12 04:46:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619063, encodeId=f6c2161906305, content=<a href='/topic/show?id=492a42862bd' target=_blank style='color:#2F92EE;'>#外显子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42862, encryptionId=492a42862bd, topicName=外显子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Dec 12 04:46:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040616, encodeId=b28e10406167b, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Dec 10 16:46:00 CST 2019, time=2019-12-10, status=1, ipAttribution=)]
    2019-12-10 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

J Clin Oncol:派姆单抗治疗难治性转移去势抵抗性前列腺癌研究

之前的研究报道了派姆单抗对程序性死亡配体1(PD-L1)阳性转移去势抵抗性前列腺癌(mCRPC)具有抗肿瘤活性。最近,有研究人员评估了派姆单抗在一个更大的mCRPC群体中的3个平行群体中的抗肿瘤活性和安全性情况。研究共包括了258名患者:群体1中包含133名,群体2中包含66名,群体3中包含59名。群体1中客观反映率为5%(95% CI, 2%到11%),群体2中客观反映率为3%(95% CI,

转移性前列腺癌该如何化疗

自2004年TAX327研究证实多西他赛联合泼尼松较米托蒽醌联合泼尼松方案显着延长mCRPC患者者总生存时间以来,多西他赛化疗在转移性前列腺癌的治疗中发挥着越来越重要的作用。

Nat Commun:转移趋势抵抗性前列腺癌基因组图谱阐释了不同的基因型具有可能的临床影响

转移去势抵抗性前列腺癌(mCRPC)具有高度复杂的基因组图谱。随着最近新治疗方法的发展,对前列腺癌的精准分层策略是需要的。最近,有研究人员对197名mCRPC患者的新鲜冷冻转移活检样本进行了全基因组测序(WGS)分析。基于基因组特性的无监督聚类分析,研究人员确定了8个不同的基因组聚类。研究人员观察到了可能的临床相关基因型,包括微卫星不稳定性(MSI)、基因组缺失中富集的同源重组缺失(HRD)、BR

Eur Urol:局部前列腺癌患者中的10年死亡率、疾病恶化和治疗相关副作用分析

ProtecT试验报道了局部前列腺癌男性的意向分析,他们随机的分配到积极监控(AM)、根治性前列腺切除和体外放射治疗中。最近,有研究人员在随机和治疗选择群体中,报道了接受不同治疗的男性的结果情况。研究发现,根据接受治疗的方法,接受AM的男性死亡率更高(AM,1.85%;手术,0.67%;放疗,0.73%),而该差异在随机群体中仍旧保持一致(p=0.08);在AM与组合放疗比较的探索性分析中,研究人

Lancet Oncol:80% BRCA突变患者有反应!奥拉帕利治疗前列腺癌患者试验发表

PARP抑制剂奥拉帕利是首个在中国问世的卵巢癌靶向新药,在美国、欧盟、日本还已获批乳腺癌适应症,其跨多个癌种的应用潜力也备受业界关注,在研适应症还包括胰腺癌和前列腺癌等。

Oncogene:拮抗剂贝沙罗汀靶向TR4核受体能够增加前列腺癌对多烯紫杉醇的敏感性

前列腺癌(PCa)是美国男性癌症死亡的第二大原因,并且转移去势抵抗性前列腺癌(mCRPC)患者没有治疗选择。多烯紫杉醇(DTX)是mCRPC的一种标准的化疗疗法。然而,对DTX的抗性是一个明显的临床问题,并且导致了半数患者对治疗没有响应。TR4核受体被报道在PCa恶化过程中具有重要的作用,然而,它与DTX抗性之间的关系仍旧未知。最近,有研究人员发现TR4在DTX化疗之后的mCRPC细胞和患者中表达